Beta-Thalassemia (beta-thal) is one of the most common inherited diseases all over the world. These patients are very susceptible to infection disease, and the mortality and morbidity of infected patients will increase. The object of this systematic review study was to determine mortality and morbidity of infected beta-thal patients with coronavirus disease 2019 (COVID-19). We searched PubMed, Elsevier, and Scholar Google to obtain related papers. The time of search was 21 June until 17 July 2020. All original and review articles and case reports were searched with key words: COVID 19, beta or beta-thalassemia (beta-thal), mortality and morbidity. Data were extracted after quality assessment of all articles. We obtained seven, 21 and six articles from PubMed, Scholar Google and Science Direct, respectively. Finally, seven articles were discussed in our study. The total number of enrolled patients was 34. Twenty-six patients carried transfusion-dependent beta-thal major (beta-TM). The most common symptoms were fever, cough, pain and dyspnea. Nine patients died. The result of this study has shown that the mortality and morbidity of infected beta-thal patients will escalate.
: A novel viral respiratory disease caused by severe acute respiratory syndrome, coronavirus 2 (SARS-COV-2), is responsible for a pandemic situation in the world. Pregnant women are susceptible to this virus due to physiologic changes in the immunologic system. The risk of some adverse pregnancy outcomes, such as death, stillbirth, preeclampsia, and intrauterine fetal distress, may increase in infected pregnant women. Infected women should be isolated and investigated, and they should admit to a designated hospital with adequate facilities and multi-disciplinary expertise to manage them. Furthermore, the chances of adverse neonatal complications, such as small for gestational age, large for gestational age, shortness of breath, thrombocytopenia with abnormal liver function, rapid heart rate, vomiting, and pneumothorax, may increase in an affected neonate. This study reviews the problems and guidelines of covid-19 in pregnancy.
28 October 2017 in Zahedan Journal of Research in Medical Sciences
Background: Iron over load will be appearing in kidney following blood transfusion. Desferal as an iron chelator can be ended renal complication. Objectives: The aim of this study is evaluation the level of β2 microglobulin in β- Thalassemia major patients for follow up proximal tubular damage. Methods: In this descriptive and analytic study 40 thalassemic patients who were treated by Desferal and 40 healthy subjects enrolled in this study randomly. For evaluation the proximal tubular damage in these groups, we measured the β-2 microglobin. Another variable such as: Ca, Mg, P and Urea of blood and K, Cr, protein and volume of urine 24 hours were measured. We compared these variables between two groups. And descriptive and analytic analyses were used. Results: The level of β2 microglobulin had significant difference in both groups, also the level of Ca, K and β-2 Globin in serum and Cr, protein and urine volume in 24 houres had significant difference. Conclusions: The higher level of β2 microglobulin in Thalassemia major patient who were treated by Desferal, show the proximal tubular damage. Keywords: Transfusion Dependent Thalassemia Major; Desferal; β2 Microglobulin